SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (375)11/20/1999 1:54:00 PM
From: Bob L  Read Replies (2) | Respond to of 666
 
"The weight of evidence seems to tilt solidly, if not overwhelmingly, to Bexxar."

I don't really understand this, as there hasn't been anything close to a direct comparison between the two. There is so much variation among patient characteristics in NHL that comparisons of small population studies of the two seem hazardous at best. Also, has anyone articulated a medical theory as to why Zevalin should have a significantly worse averse effect profile?

Or is the quoted statement based on the general preference for iodine-based products?



To: WTDEC who wrote (375)11/20/1999 2:19:00 PM
From: Vector1  Respond to of 666
 
Walter,
Pure frustration. No new info on the filing timing.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News